Advertisement
Advertisement
DCOY
D
Decoy Therapeutics Inc. Common Stock
5.90
USDSponsored
-0.15
-2.48%
May 01, 15:59 UTC -4
Closed
After-Market
5.91
0.00
+0.08%
DCOY Earnings Reports
Positive Surprise Ratio
No Data Available for DCOY
0%
Next Report
Date of Next Report
May 12, 2026
Estimate for Q1 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/--
Implied change from Q1 25 (Revenue/ EPS)
--
/--
Decoy Therapeutics Inc. Common Stock earnings per share and revenue
On Mar 31, 2026, DCOY reported earnings of -- USD per share (EPS) for Q4 25, -- the estimate of -6.00 USD, resulting in a --% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -6.51% price change (close before vs. close after earnings).
Looking ahead to Q1 26, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Amgen Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$4.85
Actual
$5.15
Surprise
+6.15%
Bristol-Myers Squibb Co.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.42
Actual
$1.58
Surprise
+10.95%
Alnylam Pharmaceuticals, Inc.
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.95
Actual
$1.99
Surprise
+108.95%
Moderna, Inc. Common Stock
Report Date
May 01, 2026 For Q1 26
Estimate
-$3.32
Actual
-$1.18
Surprise
+64.48%
Illumina Inc
Report Date
Apr 30, 2026 For Q1 26
Estimate
$1.07
Actual
$1.14
Surprise
+6.94%
Bio-Rad Laboratories, Inc. Class B
Report Date
Apr 30, 2026 For Q1 26
Estimate
$2.00
Actual
$1.89
Surprise
-5.68%
Kymera Therapeutics, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.89
Actual
-$0.71
Surprise
+21.05%
NovoCure Limited Ordinary Shares
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.52
Actual
-$0.62
Surprise
-18.52%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
-$0.32
Actual
-$0.18
Surprise
+45.22%
Pacira BioSciences, Inc. Common Stock
Report Date
Apr 30, 2026 For Q1 26
Estimate
$0.57
Actual
$0.60
Surprise
+4.42%
FAQ
What were Decoy Therapeutics Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Decoy Therapeutics Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, 0% as expectations.
How did the market react to Decoy Therapeutics Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -6.51%, changed from $7.99 before the earnings release to $7.47 the day after.
When is Decoy Therapeutics Inc. Common Stock expected to report next?
The next earning report is scheduled for May 12, 2026.
What are the forecasts for Decoy Therapeutics Inc. Common Stock's next earnings report?
Based on --
analysts, Decoy Therapeutics Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement